St. Jude Clinical Trials
- Younger than 30 years old
- Original diagnosis of osteosarcoma
- Osteosarcoma has come back in the lungs after original treatment
- Lung tumors have been removed surgically within the last 4 weeks before enrolling in the study
BMNIRN: Talazoparib Plus Irinotecan With or Without Temozolomide in Children with Refractory or Recurrent Solid Malignancies
Relapsed or refractory solid tumors
- Participant has refractory or recurrent solid tumor for which there is no standard therapy.
- Participant has had histologic verification of malignancy at original diagnosis or at the time of relapse.
- Participant is twelve (12) months to twenty-five (25) years of age at the time of enrollment on study.
- Participant life expectancy is at least eight (8) weeks.
This study is open to St. Jude patients only.
- Known or suspected neuroblastoma or pheochromocytoma
- At least 1 year old
- Age 17 or younger
- Diagnosis of retinoblastoma that did not go away with treatment or came back after treatment
- Younger than 19 years old
- Newly diagnosed, advanced stage, high-risk neuroblastoma
- Histologic proof of neuroblastoma or positive bone marrow for tumor cells with increased urine catecholamine
- Adequate kidney and liver functions
This study is currently open only to patients at St. Jude Children's Research Hospital.
- 7 years old or younger
- Part I
- Diagnosed with retinoblastoma and has not received any treatment OR
- Diagnosed with cataracts and has not received any treatment OR
- Diagnosed with glaucoma and has not received any treatment
- Part II
- Referred to an eye doctor to check for leukocoria or other eye conditions
- Part III
- Diagnosed with retinoblastoma and is receiving treatment
RMS13: Chemotherapy, Surgery and Proton Beam Radiation Therapy in Treating Patients with Newly Diagnosed Rhabdomyosarcoma
Rhabdomyosarcoma (low-risk, intermediate-risk and high-risk)
- Newly diagnosed rhabdomyosarcoma
- Younger than 22 years (eligible until 22nd birthday)
- No previous treatment with chemotherapy or radiation therapy
- Has one of these types of tumors:
- Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) or synchronous extraneural ATRTs
- ATRTs or malignant rhabdoid tumors (MRTs) that have come back after previous treatment (recurrent disease)
- ATRTs or MRTs that are growing after previous treatment (progressive disease)
- 21 years of age or younger
SJRET6: Combination Chemotherapy in Treating Patients with Newly Diagnosed, Previously Untreated Intraocular Retinoblastoma
- Newly diagnosed retinoblastoma that has not spread beyond the eye
- Has not received previous treatment with chemotherapy or radiation therapy
- Patients who have been diagnosed with retinoblastoma in one eye who did not receive chemotherapy, but then developed retinoblastoma in the opposite eye
Collaborative Clinical Trials
A031102: Standard-Dose Combination Chemotherapy Compared to High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
- 14 years old or older
- Diagnosis of germ cell tumor (GCT)
- Previously received 3 to 6 cycles of cisplatin-based chemotherapy
- No more than one prior line of chemotherapy
- No prior treatment with high-dose chemotherapy
ADV1312: WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Relapsed or refractory solid tumors
- Participant is >12 months and < 21 years of age at the time of study entry.
- Participant has had histologic verification of malignancy at original diagnosis or relapse.
- Participant has serum tumor markers including alpha-fetoprotein or beta-HCG.
- Participant has a relapsed or refractory solid tumor.
ADV1414: Phase I Study of Selinexor to Treat Patients with Recurrent and Refractory Pediatric Solid Tumors
- Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
- Fully recovered from the acute toxic effects of all prior anticancer therapy
- At least 1 but not more than 21 years of age
- Able to swallow tablets whole
- 12 months old or older and younger than 21 years old
- Part A - Non-central nervous system (CNS) tumor that returned after treatment or did not respond to treatment
- Part B – CNS tumor that returned after treatment or did not respond to treatment
- No other proven therapy options
- 12 months to 21 years old
- Able to swallow whole tablets
- Diagnosis of recurrent or refractory solid tumor, including CNS tumor and lymphoma
Solid Tumor, CNS Tumor
- 12 months to 21 years old
- Diagnosis of recurrent or refractory solid tumor, including CNS tumor
LILOLA: A Study of Olaratumab Alone and in Combination with Standard Chemotherapies in Children with Cancer
- Younger than 18 years old
- Diagnosis of solid tumor that has not responded to treatment or came back after treatment (excluding melanoma and lymphomas)
MEK116: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Relapsed or refractory solid tumor
- Participant is at least one month old and younger than 18 years old at the time of signing the informed consent (in Part A, participants < 2 years of age are not included).
- Participant has a histologically confirmed solid tumor
- Participant has a disease that is relapsed or refractory to all potentially curative standard treatment regimens, or has a disease for which there is no standard treatment regimen that is potentially curative.
- Between 6 months and 18 years old with diagnosis of advanced melanoma or PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma, or MSI-H solid tumor
- Between 3 and 18 years of age with relapsed or refractory classical Hodgkin lymphoma
- Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
- Appropriate liver and kidney functions
NBL1232: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-High Risk Neuroblastoma
- Participant has been enrolled on ANBLB1 (ANBL00B1).
- Participant has newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma.
- Participant is less than 12 months (Group A) and less than 18 months (Group B and Group C) of age at diagnosis.
- Participant has histologically or cytologically confirmed diagnosis:
- Nonrhabdomyosarcoma of soft tissue
- Ewing sarcoma
- Osteosarcoma at any site
- Participant must be greater than 3 years of age and < 40 years of age.
- Participant has not had any prior radiotherapy to the treatment site.